Jack Ryan Reifert has extensive experience in neuroscience research and industrial research. He received his Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB, focusing on amyloid beta induced neurodegeneration and the involvement of tau. He has held postdoctoral positions at UCSB studying bacterial peptide display to inhibit ovarian cancer metastasis and at UCSD investigating wnt/β-catenin signaling in rheumatoid arthritis. Reifert has worked at several companies, contributing to FDA approval of Bendamustine and coordinating product releases. He is currently a postdoctoral fellow at UCSB studying targeted inhibition of proteases in ovarian cancer metastasis.